https://doi.org/10.55788/db2611e8
The presented retrospective cohort study included 37,383 individuals from the Mass General Brigham Biobank from 2010–2020 [1]. In this cohort, Dr Shady Abohashem (Massachusetts General Hospital, MA, USA) and colleagues assessed the efficacy of lifestyle factors, measured by a lifestyle score, on the risk of cardiovascular disease (CVD) in people with and without anxiety and/or depression. The study also evaluated neuro-inflammatory markers like stress-related neural activity. The primary endpoint was a lifestyle score named LS (A) that was calculated as a composite of favourable lifestyle behaviours: exercise at ≥500 metabolic equivalents of task (METs)/week, average sleep of 7–9 hours daily, and alcohol of 1–14 units/week.
In a Cox model that adjusted for CVD risk factors, an overall lower chance of MACE (i.e. myocardial infarction, unstable angina, or stroke) was associated with the highest score category of lifestyle over 10 years (HR 0.53; 95% CI 0.48–0.59). Also, each change of lifestyle category was linked to a reduced risk of MACE (HR 0.82; 95% CI 0.79–0.84). Assessing people without versus people with anxiety and/or depression showed a greater decrease in risk for people with anxiety and/or depression, translating into an additional relative risk reduction of 64% with a P<0.001 for effect modification.
In a subset of individuals with data on neuro-immune measures, LS (A) was linked to a graded reduction in stress-related neural activity on FDG PET/CT imaging. For heart rate variability and C-reactive protein, significant associations to LS (A) were also observed. A mediation analysis further suggested that the neuro-inflammatory pathways may be partially involved in the benefit of a favourable lifestyle. Future research investigating measures of lifestyle modification could be specifically beneficial to individuals with anxiety and/or depression by providing preventive recommendations for this population.
- Abohashem S, et al. Lifestyle behaviours associate with greater reduction in cardiovascular disease risk among people with anxiety and/or depression: mediated by a reduction in stress related brain activity. Session 910-05, ACC 2024 Scientific Session, 6–8 April, Atlanta, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Self-expanding versus balloon-expendable TAVR in patients with small aortic annuli Next Article
SGLT2 inhibition in heart failure more advantageous for women than men »
« Self-expanding versus balloon-expendable TAVR in patients with small aortic annuli Next Article
SGLT2 inhibition in heart failure more advantageous for women than men »
Table of Contents: ACC 2024
Featured articles
Matters of the heart: late-breaking news from the American College of Cardiology
Heart Failure and Cardiomyopathy
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes
IMPROVE-HCM: Promising results for ninerafaxstat in non-obstructive HCM
Acute Coronary Syndrome and Acute Myocardial Infarction
ACS: Necessary DAPT after PCI may be shorter than currently advised
AEGIS-II: ApoA-1 did not reduce MACE in patients with myocardial infarction but may provide benefit in patients with high LDL levels
REDUCE-AMI: Re-evaluating the role of routine beta-blockade in patients with acute myocardial infarction
Interventional Cardiology in 2024
Self-expanding versus balloon-expendable TAVR in patients with small aortic annuli
Safety of TAVI non-inferior to SAVR for patients with lower surgical risk
Interatrial shunt for HF: neutral primary endpoint but potential benefit in HFrEF
Peripheral artery disease: procedure-guidance by IVUS superior to angiography
IVUS-guided PCI beats angiography in patients with acute coronary syndrome
Addressing frailty in patients undergoing TAVR
Novel Developments in Risk Factor Management
Preventive PCI of vulnerable intracoronary plaque leads to favourable outcomes
KARDIA-2: Add-on zilebesiran effectively lowers blood pressure
BRIDGE-TIMI 73a: Olezarsen halves triglyceride levels
Plozasiran: A novel approach to severe hypertriglyceridaemia
High-risk and very high-risk patients meet LDL-cholesterol targets with lerodalcibep
No cardioprotective effect of ACE inhibitors in patients with cancer
Best of Posters
SGLT2 inhibition in heart failure more advantageous for women than men
Anxiety and depression: Lifestyle influential in MACE prevention
Meet the Trialists
Related Articles
December 7, 2020
Study links fracking operations to worsening heart failure
October 26, 2021
2021 ESC Guidelines on Heart Failure
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com